Research analysts at Goldman Sachs Group Inc. lifted their price target on shares of Hikma Pharmaceuticals (LON:HIK) from GBX 1,180 ($19.15) to GBX 1,200 ($19.48) in a report released on Wednesday, Analyst Ratings News reports. The firm currently has a “neutral” rating on the stock. Goldman Sachs Group Inc.’s price target would indicate a potential […]
Hikma Pharmaceuticals Given New GBX 1,200 Price Target at Goldman Sachs Group Inc. (HIK) is a post from: Zolmax
The post Hikma Pharmaceuticals Given New GBX 1,200 Price Target at Goldman Sachs Group Inc. (HIK) appeared first on Zolmax.
